



NORWAY

Recent and planned developments in pharmaceutical policies 2016

Special topic: Pricing and reimbursement policies for biosimilars

D E V E L O P M E N T S	CHANGES IN PRICING	CHANGES IN REIMBURSEMENT
	<p><i>Changes in formula for max pharmacy mark-up, implemented 1.1.2016:</i></p> <ul style="list-style-type: none"> • <i>More regressive: Pharmacy Purchasing Price > 200 NOK/22 Euro: percentage reduced from 3 to 2,5 %</i> • <i>Fixed addition for addictive drugs/narcotics increased from 10 to 15 NOK (1,6 Euro)</i> 	<p><i>More medicines were transferred from the National Insurance Scheme to the hospitals budget:</i></p> <ul style="list-style-type: none"> • <i>New Hepatite C</i> • <i>Growth hormones</i> • <i>Blood coagulation factors</i> • <i>Anemia</i>
S P E C I A L T O P I C	OTHER CHANGES	
	<p><i>System for evaluation of technologies (incl. medicines) has developed:</i></p> <ul style="list-style-type: none"> • <i>Horizon Scanning in place</i> • <i>NOMA identifies new medicines at day 120 in the Market Authorization-process.</i> • <i>NOMA notifies Hospital-system of coming new substances.</i> • <i>Results:</i> <ul style="list-style-type: none"> - <i>Early decision on whether to perform a technology assessment or not.</i> - <i>Better, and more timely, basis for hospitals decision whether to make use of a new medicine or not (and for negotiations with the MA-holder).</i> <p><i>Mind the gap! What happens with patients after clinical trial has ended and before hospitals have made decision?</i></p>	
POLICIES FOR BIOSIMILARS		
<p><i>Hospitals:</i></p> <ul style="list-style-type: none"> • <i>Big selling biosimilars are funded by hospitals.</i> • <i>The hospitals purchasing cooperation make tenders.</i> • <i>Degree of competition influences price.</i> • <i>When biosimilar comes with substantial rebate, clinicians see the point of switching the patients.</i> <p><i>Reimbursement by National Insurance Scheme (outpatient use):</i></p> <ul style="list-style-type: none"> • <i>The law prohibits substitution of biological medicines in pharmacies.</i> • <i>The Ministry of Health and Care Services may propose to change the law:</i> • <i>Depending on the results of the NOR-SWITCH study.</i> • <i>When system for tracing batches is implemented.</i> • <i>Potential for savings: insulins? But what about the administration/device?</i> <ul style="list-style-type: none"> • <i>The potential for big savings is on the hospitals' budget!</i> 		